MA39163A1 - Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine - Google Patents
Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexineInfo
- Publication number
- MA39163A1 MA39163A1 MA39163A MA39163A MA39163A1 MA 39163 A1 MA39163 A1 MA 39163A1 MA 39163 A MA39163 A MA 39163A MA 39163 A MA39163 A MA 39163A MA 39163 A1 MA39163 A1 MA 39163A1
- Authority
- MA
- Morocco
- Prior art keywords
- methylpyrrolidin
- methanone
- triazol
- imidazol
- benzo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
L'invention concerne des formes cristallines de (s)-(2-(6-chloro-7-méthyl-1h-benzo[d]imidazol-2- yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone, des procédés de préparation de celles-ci, des compositions pharmaceutiques contenant de telles formes cristallines, des compositions pharmaceutiques préparées à partir de telles formes cristallines ainsi que leur utilisation en tant que médicament, notamment en tant qu'antagonistes des récepteurs de l'orexine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2013060596 | 2013-12-03 | ||
PCT/IB2014/066508 WO2015083070A1 (fr) | 2013-12-03 | 2014-12-02 | Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39163A1 true MA39163A1 (fr) | 2017-11-30 |
MA39163B1 MA39163B1 (fr) | 2018-09-28 |
Family
ID=52282786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39163A MA39163B1 (fr) | 2013-12-03 | 2014-12-02 | Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine |
Country Status (31)
Country | Link |
---|---|
US (1) | US9914720B2 (fr) |
EP (1) | EP3077389B1 (fr) |
JP (1) | JP6496733B2 (fr) |
KR (1) | KR102361418B1 (fr) |
CN (1) | CN105793257B (fr) |
AU (1) | AU2014358742B2 (fr) |
CA (1) | CA2929423C (fr) |
CL (1) | CL2016001342A1 (fr) |
CY (1) | CY1119695T1 (fr) |
DK (1) | DK3077389T3 (fr) |
EA (1) | EA030137B1 (fr) |
ES (1) | ES2651475T3 (fr) |
HK (1) | HK1225731B (fr) |
HR (1) | HRP20171773T1 (fr) |
HU (1) | HUE035731T2 (fr) |
IL (1) | IL245923B (fr) |
LT (1) | LT3077389T (fr) |
MA (1) | MA39163B1 (fr) |
MX (1) | MX364208B (fr) |
MY (1) | MY179862A (fr) |
NO (1) | NO3077389T3 (fr) |
NZ (1) | NZ721438A (fr) |
PH (1) | PH12016500988B1 (fr) |
PL (1) | PL3077389T3 (fr) |
PT (1) | PT3077389T (fr) |
SA (1) | SA516371231B1 (fr) |
SI (1) | SI3077389T1 (fr) |
TW (1) | TWI664177B (fr) |
UA (1) | UA119549C2 (fr) |
WO (1) | WO2015083070A1 (fr) |
ZA (1) | ZA201604499B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2855453T1 (sl) | 2012-06-04 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Benzimidazol-prolinski derivati |
UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
LT3077391T (lt) | 2013-12-04 | 2018-10-25 | Idorsia Pharmaceuticals Ltd | Benzimidazolo prolino darinių panaudojimas |
WO2018202689A1 (fr) * | 2017-05-03 | 2018-11-08 | Idorsia Pharmaceuticals Ltd | Préparation de dérivés de l'acide 2-([1,2,3]triazol-2-yl)-benzoïque |
BR112022020924A2 (pt) | 2020-04-19 | 2023-02-14 | Idorsia Pharmaceuticals Ltd | Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitável |
WO2022166768A1 (fr) * | 2021-02-02 | 2022-08-11 | 南京明德新药研发有限公司 | Composé tétrahydropyrrolocyclique et son application |
WO2023160004A1 (fr) * | 2022-02-25 | 2023-08-31 | 南京知和医药科技有限公司 | Composé à cycle fusionné ayant une activité analgésique, son procédé de préparation et son utilisation |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3282927A (en) | 1964-05-21 | 1966-11-01 | Bristol Myers Co | 5-phenyl-4-thiazolylpenicillins |
DE60110066T2 (de) | 2000-06-16 | 2006-02-02 | Smithkline Beecham P.L.C., Brentford | Piperidine zur verwendung als orexinrezeptorantagonisten |
CA2425185A1 (fr) | 2000-10-06 | 2002-04-11 | Stephane De Lombaert | Derives de benzimidazole et d'indole en tant que modulateurs des recepteurs de la corticoliberine |
WO2002044172A1 (fr) | 2000-11-28 | 2002-06-06 | Smithkline Beecham P.L.C. | Derives de la morpholine utilises comme antagonistes des recepteurs de l'orexine |
WO2002089800A2 (fr) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | Derives d'amines cycliques n-aroyl utilises comme antagonistes du recepteur d'orexine |
ES2299567T3 (es) | 2001-05-05 | 2008-06-01 | Smithkline Beecham Plc | N-aroilaminas ciclicas. |
JP4399256B2 (ja) * | 2001-06-28 | 2010-01-13 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体アンタゴニストとしてのn−アロイル環状アミン誘導体 |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
EP1539747B1 (fr) | 2002-09-18 | 2006-11-02 | Glaxo Group Limited | Amines cycliques n-aroyle utilisees comme antagonistes du recepteur d'orexine |
GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
RU2378257C2 (ru) | 2004-03-01 | 2010-01-10 | Актелион Фармасьютиклз Лтд | Замещенные производные 1,2,3,4-тетрагидроизохинолина |
EP1998774A1 (fr) | 2006-03-15 | 2008-12-10 | Actelion Pharmaceuticals Ltd. | Derives de tetrahydroisoquinoleine pour renforcer la fonction de la memoire |
WO2007135527A2 (fr) * | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Composés de benzimidazolyle |
MX2009001432A (es) | 2006-08-15 | 2009-02-17 | Actelion Pharmaceuticals Ltd | Compuestos de azetidina. |
WO2008038251A2 (fr) | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | Dérivés du 3-aza-bicyclo[3.1.0]hexane |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
AR064561A1 (es) | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
WO2008087611A2 (fr) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Dérivés de pyrrolidine et de piperidine |
CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
WO2008139416A1 (fr) | 2007-05-14 | 2008-11-20 | Actelion Pharmaceuticals Ltd | Dérivés de 2-cyclopropyl-thiazole |
EP2150115B1 (fr) | 2007-05-23 | 2013-09-18 | Merck Sharp & Dohme Corp. | Antagonistes du récepteur de la cyclopropylpyrrolidine orexine |
GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
JP2010531871A (ja) | 2007-07-03 | 2010-09-30 | アクテリオン ファーマシューティカルズ リミテッド | 3−アザ−ビシクロ[3.3.0]オクタン化合物 |
AU2008270294A1 (en) | 2007-07-03 | 2009-01-08 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
AU2008281399A1 (en) | 2007-07-27 | 2009-02-05 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
JP2010534646A (ja) | 2007-07-27 | 2010-11-11 | アクテリオン ファーマシューティカルズ リミテッド | トランス−3−アザ−ビシクロ[3.1.0]ヘキサン誘導体 |
EP2207778A2 (fr) | 2007-09-24 | 2010-07-21 | Actelion Pharmaceuticals Ltd. | Pyrrolidines et pipéridines en tant qu'antagonistes du récepteur de l'orexine |
PE20091010A1 (es) | 2007-10-10 | 2009-08-08 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroquinolina |
ES2385699T3 (es) | 2008-02-21 | 2012-07-30 | Actelion Pharmaceuticals Ltd. | Derivados de 2-aza-biciclo-[2,2,1]heptano |
GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
US20110105491A1 (en) | 2008-07-07 | 2011-05-05 | Hamed Aissaoui | Thiazolidine compounds as orexin receptor antagonists |
WO2010038200A1 (fr) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Composés d'oxazolidine utilisables en tant qu'antagonistes des récepteurs à orexine |
JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
WO2010060470A1 (fr) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Dérivés de la pipéridine utiles en tant qu’antagonistes du récepteur de l’orexine |
WO2010060471A1 (fr) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Dérivés de la pipéridine utiles en tant qu’antagonistes du récepteur de l’orexine |
AR074238A1 (es) | 2008-12-02 | 2010-12-29 | Glaxo Group Ltd | Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende |
KR20110091581A (ko) | 2008-12-02 | 2011-08-11 | 글락소 그룹 리미티드 | N-{[1r,4s,6r-3-(2-피리디닐카르보닐)-3-아자비시클로[4.1.0]헵트-4-일]메틸}-2-헤테로아릴아민 유도체 및 그의 용도 |
GB0823467D0 (en) * | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
WO2010122151A1 (fr) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | 3 -azabicyclo [4.1.0] heptanes utilisés comme antagonistes de l'orexine |
TW201209037A (en) | 2010-08-24 | 2012-03-01 | Actelion Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
EP2638008B1 (fr) | 2010-11-10 | 2015-07-01 | Actelion Pharmaceuticals Ltd | Dérivés de lactame utiles en tant qu'antagonistes du récepteur de l'orexine |
JP5987005B2 (ja) | 2011-02-18 | 2016-09-06 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | オレキシン拮抗薬として有用な新規なピラゾール及びイミダゾール誘導体 |
CN103917538B (zh) | 2011-11-08 | 2016-08-24 | 埃科特莱茵药品有限公司 | 2-(1,2,3-三唑-2-基)苯甲酰胺及3-(1,2,3-三唑-2-基)吡啶酰胺衍生物 |
SI2855453T1 (sl) * | 2012-06-04 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Benzimidazol-prolinski derivati |
BR112015007516A2 (pt) | 2012-10-10 | 2017-07-04 | Actelion Pharmaceuticals Ltd | antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona |
CA2902135A1 (fr) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Derives d'amide d'azetidine en tant qu'antagonistes des recepteurs d'orexine |
UA119151C2 (uk) * | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
LT3077391T (lt) | 2013-12-04 | 2018-10-25 | Idorsia Pharmaceuticals Ltd | Benzimidazolo prolino darinių panaudojimas |
-
2014
- 2014-12-02 MY MYPI2016701997A patent/MY179862A/en unknown
- 2014-12-02 CA CA2929423A patent/CA2929423C/fr active Active
- 2014-12-02 HU HUE14824107A patent/HUE035731T2/hu unknown
- 2014-12-02 JP JP2016536109A patent/JP6496733B2/ja active Active
- 2014-12-02 MX MX2016007215A patent/MX364208B/es active IP Right Grant
- 2014-12-02 WO PCT/IB2014/066508 patent/WO2015083070A1/fr active Application Filing
- 2014-12-02 KR KR1020167017644A patent/KR102361418B1/ko active IP Right Grant
- 2014-12-02 PL PL14824107T patent/PL3077389T3/pl unknown
- 2014-12-02 EA EA201600435A patent/EA030137B1/ru not_active IP Right Cessation
- 2014-12-02 MA MA39163A patent/MA39163B1/fr unknown
- 2014-12-02 US US15/101,768 patent/US9914720B2/en active Active
- 2014-12-02 EP EP14824107.8A patent/EP3077389B1/fr active Active
- 2014-12-02 AU AU2014358742A patent/AU2014358742B2/en active Active
- 2014-12-02 NZ NZ721438A patent/NZ721438A/en unknown
- 2014-12-02 CN CN201480065274.7A patent/CN105793257B/zh active Active
- 2014-12-02 SI SI201430489T patent/SI3077389T1/en unknown
- 2014-12-02 TW TW103141828A patent/TWI664177B/zh active
- 2014-12-02 DK DK14824107.8T patent/DK3077389T3/da active
- 2014-12-02 LT LTEP14824107.8T patent/LT3077389T/lt unknown
- 2014-12-02 NO NO14824107A patent/NO3077389T3/no unknown
- 2014-12-02 UA UAA201607114A patent/UA119549C2/uk unknown
- 2014-12-02 PT PT148241078T patent/PT3077389T/pt unknown
- 2014-12-02 ES ES14824107.8T patent/ES2651475T3/es active Active
-
2016
- 2016-05-26 PH PH12016500988A patent/PH12016500988B1/en unknown
- 2016-05-30 IL IL245923A patent/IL245923B/en active IP Right Grant
- 2016-05-30 SA SA516371231A patent/SA516371231B1/ar unknown
- 2016-06-02 CL CL2016001342A patent/CL2016001342A1/es unknown
- 2016-07-01 ZA ZA2016/04499A patent/ZA201604499B/en unknown
- 2016-12-13 HK HK16114145A patent/HK1225731B/zh unknown
-
2017
- 2017-11-16 HR HRP20171773TT patent/HRP20171773T1/hr unknown
- 2017-12-12 CY CY20171101301T patent/CY1119695T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39163A1 (fr) | Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine | |
MA39164B1 (fr) | Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine | |
BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
IN2012DN02730A (fr) | ||
IN2012DN00754A (fr) | ||
MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
CL2016002238A1 (es) | Compuestos derivados de 3-(5-oxo-4,5-dihidro-1h-tetrazol-1-il)-5,6-dihidropiridin-2(1h)-ona sustituidos con tetrazolona, inhibidores de monocilglicerol aciltransferasa 2 (mgat2); composiciones farmacológicas; útiles para tratar la diabetes, hipeglucemia, intolerancia a la glucosa, resistencia a la insulina, hiperinsulinemia, enfermedad al hígado graso no alcohólico, retinopatía, entre otras. | |
MA33132B1 (fr) | Derives pyrazole utilises comme antagonistes du recepteur ccr4 | |
MA29816B1 (fr) | Composes de benzimidazole thiophene | |
UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
UA100877C2 (ru) | Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3) | |
PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
UA97826C2 (ru) | Быстро диссоциирующие антагонисты рецептора 2 дофамина | |
MX2010009574A (es) | 2-aminoquinolinas. | |
MA38358A1 (fr) | Formulations de composés organiques | |
UA117154C2 (uk) | Антагоністи s1p3 | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
EA200970553A1 (ru) | Пиперидиниламинопиридазины и их применение в качестве быстро диссоциирующих антагонистов рецептора допамина 2 | |
MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
PE20190382A1 (es) | Derivados etinilo | |
MX2017015047A (es) | Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico. | |
CL2008000302A1 (es) | Compuestos derivados de 2-oxo-1,4-diazaespiro[4.5]dec-3-en-1-il-acetamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de psicosis, esquizofrenia, demencia y trastorno por falta de atencion. |